Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. Alexion is the global leader in complement inhibition and has developed and commercializes the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG). In addition, Alexion has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D).
Industry sector: Medical
Sector classification: Pharmaceutical preparations
Deep Learning based analysis and prediction model for Alexion Pharmaceuticals, Inc. (ALXN) stock is a 2nd Generation Non-linear Autoregressive (NAR) model based on the LSTM/GRU Recurrent Neural Network architecture.
Model is in the production pipeline since Oct. 2, 2015.
Market data for ALXN model training are being downloaded from the
Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are accounted for in this model in the form of the historical data coincided with outbreaks and other global events in the past used to train ML prediction model for ALXN.
Model is being retrained on a regular basis.
|% Held by Insiders||4.35%|
|% Held by Institutions||95.89%|
|EPS (last reported FY)||$5.16|
|EPS (last reported Q)||$1.53|
|EPS, estimated (last reported Q)||$1.29|
|Total revenues||$4 B|
|Net income||$0 B|